NeurogesX to Present at March 2011 Investor Conferences

SAN MATEO, Calif., Feb. 28, 2011 /PRNewswire/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at three upcoming investor conferences: The Citi 2011 Global Health Care Conference, March 1 - 3, in New York, NY; The Cowen and Company 31st Annual Health Care Conference, March 7 - 9, in Boston, MA; and The ROTH 23rd Annual OC Growth Stock Conference, March 13 - 16, in Laguna Niguel, CA.

Mr. DiTonno and Stephen Ghiglieri, SVP, COO and CFO, will be available to respond to questions and to participate in one-on-one meetings with investors attending both conferences.

Event: Citi 2011 Global Healthcare Conference Date: Wednesday, March 2, 2011 Time: 2:00 PM Place: The Hilton New York Hotel, New York, NY (Beekman Parlor) Event: Cowen and Company 31st Annual Health Care Conference Date: Monday, March 7, 2011 Time: 4:45 PM Place: The Boston Marriott Copley Place, Boston, MA Event: ROTH 23rd Annual OC Growth Stock Conference Date: Monday, March 14, 2011 Time: 11:00 AM Place: The Ritz Carlton, Laguna Niguel, CA (Track 9)

Presentations will be webcast live and archived for 90 days on the investor relations section of NeurogesX' website at http://www.neurogesx.com/.

About NeurogesX, Inc.

NeurogesX, Inc. is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated neuropathy (HIV-AN) also known as HIV-distal sensory neuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient dosing is underway in a Phase 2 clinical trial in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated certain of these compounds in vitro and in vivo.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: the potential submission to the U.S. Food and Drug Administration of a supplemental new drug application for label expansion of Qutenza. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the commercialization of Qutenza, including with respect to manufacture and supply of Qutenza; unexpected adverse side effects of Qutenza; physician or patient reluctance to use Qutenza, despite the Company's efforts and strategies to commercialize Qutenza; and difficulties or delays in the further development of Qutenza and efforts towards label expansion; and potential competitors and competitive products. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc. The Ruth Group Stephen Ghiglieri Sara Pellegrino (investors) Chief Financial Officer [phone] [phone] [e-mail] Jason Rando (media) [phone] [e-mail]

NeurogesX, Inc.

CONTACT: NeurogesX, Inc.: Stephen Ghiglieri, Chief Financial Officer,
[phone]; The Ruth Group: Sara Pellegrino (investors), [phone],
[e-mail], or Jason Rando (media), [phone],
[e-mail]

Web Site: http://www.neurogesx.com/